LEG
70
4
COF
54
5
KEY
70
3
MS
55
2
EXR
40
10
DVA
65
-7
CRM
15
3
ESS
28
8
STI
18
11
LB
27
9
AEE
73
2
XRX
32
8
ZBH
53
3
MSFT
34
3
DAL
68
7
WFC
63
3
EFX
29
7
ETR
60
2
PFG
65
4
BDX
54
-6
LEG
70
4
COF
54
5
KEY
70
3
MS
55
2
EXR
40
10
DVA
65
-7
CRM
15
3
ESS
28
8
STI
18
11
LB
27
9
AEE
73
2
XRX
32
8
ZBH
53
3
MSFT
34
3
DAL
68
7
WFC
63
3
EFX
29
7
ETR
60
2
PFG
65
4
BDX
54
-6
Financhill
Back

Cidara Therapeutics, Inc. Stock Predictions

The Next Phase of AI Is Not About Chat

*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com
Buy
58

CDTX
Cidara Therapeutics, Inc.

Last Price:
$221.38
Seasonality Move:
-12.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Most Pre-IPO Big Tech Shifts Look Like This at the Start

*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com

Cidara Therapeutics, Inc. Stock Forecast

  • Over the next 52 weeks, Cidara Therapeutics, Inc. has on average historically risen by 99.8% based on the past 10 years of stock performance.
  • Cidara Therapeutics, Inc. has risen higher in 4 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 40%
  • Is Cidara Therapeutics, Inc. Stock Undervalued?
    The current Cidara Therapeutics, Inc. [CDTX] share price is $221.38. The Score for CDTX is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.
  • CDTX is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.

Will Cidara Therapeutics, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Cidara Therapeutics, Inc. has on average historically risen by 99.8% based on the past 10 years of stock performance.

Cidara Therapeutics, Inc. Stock Rating

Buy
58
Cidara Therapeutics, Inc. (CDTX) is a Buy

Is Cidara Therapeutics, Inc. overpriced?

  • Cidara Therapeutics, Inc. has risen higher in 4 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 40%

Cidara Therapeutics, Inc. Stock Price History

Is CDTX stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CDTX is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
cidara.com

52-Week Data

52-Week High:
221.42
52-Week Low:
15.22

Prediction Charts

Market Cap:
7B
Price in USD:
221.38
Volume:
0
Beta:
1.55

Technical Analysis

SMA50:
220.84
SMA100:
165.97
SMA200:
104.87
52-Wk Change:
942.77%

Stock Predictions

  • Is Cidara Therapeutics, Inc. stock public?
    Yes, Cidara Therapeutics, Inc. is a publicly traded company.
  • What is the Cidara Therapeutics, Inc. stock quote today?
    The Cidara Therapeutics, Inc. stock price is 221.38 USD today.
  • How to buy Cidara Therapeutics, Inc. stock online?
    You can buy Cidara Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Jan-20 221.38 221.38 221.38 221.38
Jan-21 221.38 221.38 221.38 221.38
Jan-22 221.38 221.38 221.38 221.38
Jan-23 221.38 221.38 221.38 221.38
Jan-26 221.38 221.38 221.38 221.38
Jan-27 221.38 221.38 221.38 221.38
Jan-28 221.38 221.38 221.38 221.38
Jan-29 221.38 221.38 221.38 221.38
Jan-30 221.38 221.38 221.38 221.38
Feb-2 221.38 221.38 221.38 221.38
Feb-3 221.38 221.38 221.38 221.38
Feb-4 221.38 221.38 221.38 221.38
Feb-5 221.38 221.38 221.38 221.38
Feb-6 221.38 221.38 221.38 221.38

Cidara Therapeutics, Inc. Earnings

Cidara Therapeutics, Inc. Earnings Report: Per Share Cidara Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Cidara Therapeutics, Inc. Forecast Revenue Growth

Cidara Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Cidara Therapeutics, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $1.42 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.21 per share, and an increase next year of $0.59 per share.

* Cidara Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.